



Marksans Pharma Ltd.

Date: July 31, 2024

BSE Limited

Corporate Relation Department
PhirozeJeejeeboi Towers,
Dalal Street,
Mumbai - 400001.
Scrip Code: 524404

National Stock Exchange of India Limited

Listing Department
Exchange Plaza, C-1, Block-G,
Bandra-Kurla Complex,
Bandra (East), Mumbai - 400051.
Symbol: MARKSANS

Sub: Newspaper Publication

Dear Sir/Madam,

Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, kindly find enclosed herewith copies of newspaper advertisement published in Business Standard (English) and Lakshadeep (Marathi) today i.e. July 31, 2024 intimating "Notice to shareholders regarding transfer of equity shares of the Company to the Investor Education and Protection Fund".

You are requested to note the above in your records.

Thanking You.

Yours faithfully,
For **Marksans Pharma Limited**

HarshavardhanPanigrahi
Company Secretary

Encl: As above

Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara,
Andheri (W), Mumbai - 400 053 • Tel.: +91 22 4001 2000 • E-mail: info@marksanspharma.com

www.marksanspharma.com

**NAGA DHUSNERI GROUP LIMITED**

CIN: L01132WB1918PLC003029,

Regd. Office: 'Dhusneri House' 4A, Woodburn Park, Kolkata-700020

Ph. No.: +91 33 2280 1950 (5 Lines), Fax (033) 22878995

E-mail: mail@nagadhunserigroup.com; Website: www.nagadhunserigroup.com

NOTICE OF 106TH ANNUAL GENERAL MEETING, INFORMATION ON E-VOTING AND BOOK CLOSURE

Notice is hereby given that the 106th Annual General Meeting (AGM) of Naga Dhusneri Group Limited is scheduled to be held on **Friday, 23rd August, 2024 at 12:00 Noon (IST) through Video Conferencing ("VC") or Other Audio Visual Means ("OAVM")** to transact the business as set forth in the Notice dated 29th May, 2024 convening the AGM. The said Notice together with the Annual Report for the Financial Year ended 31st March, 2024 has been sent to Members through electronic mode on 30th July, 2024. The Members can attend and participate at the ensuing AGM through VC / OAVM facility provided by National Securities Depository Limited ("NSDL"). The business as mentioned in the said notice will be conducted through e-voting facilities provided by NSDL. The details are given below:

- The **Remote e-voting period shall commence on Tuesday, 20th August, 2024 at 09.00 A.M and shall end on Thursday, 22nd August, 2024 at 05.00 P.M.** Further, remote e-voting shall not be allowed beyond the said date and time.
- Notice of the AGM is available on the website of the Company at www.nagadhunserigroup.com. NSDL's website at <http://www.evoting.nsdl.com> and of the Stock Exchange where the equity shares of the Company are listed i.e. www.nseindia.com.
- Members holding shares either in physical or dematerialized form as on the **cut-off date i.e. Friday, 16th August, 2024** are only entitled to vote on all the resolutions set forth in the Notice.
- Members who have acquired shares of the Company and became the Member of the Company after the dispatch of Notice and holding shares as on the cut-off date i.e. Friday, 16th August, 2024, may obtain the user ID and Password by sending a request at evoting@nsdl.co.in or mpdlco@yahoo.com.
- Those Members / Shareholders, who will be present in the AGM through VC / OAVM facility and have not casted their vote on the Resolutions through remote e-voting or are otherwise not barred from doing so, shall be eligible to vote through e-voting system in the AGM using e-voting platform provided by NSDL.
- Members may participate in the AGM even after exercising their right to vote through remote e-voting but shall not be allowed to vote again in the Annual General Meeting.
- A person whose name is recorded in the Register of Members or Register of Beneficial Owners maintained by the depositories as on the cut-off date shall only be entitled to avail the facility of remote e-voting as well as voting at the AGM.
- The detailed procedure and instruction for remote e-voting and e-voting during the AGM is given in the Notice of the AGM.
- Pursuant to Section 91 of the Companies Act, 2013, the **Register of Members and Share Transfer Books of the Company will remain closed from Saturday, 17th August, 2024 till Friday, 23rd August, 2024 (both days inclusive)**.
- In case of any query / grievance with respect to Remote E-voting, Members may refer to the Frequently Asked Questions (FAQs) for Shareholders and Remote E-voting User Manual for Shareholders available under the Downloads section of NSDL's e-voting website or contact / Ms. Pallavi Mhatre, Assistant Manager, NSDL at toll free no. 1800-2244-30 or at E-mail ID evoting@nsdl.co.in. Members are requested to refer to the Newspaper Advertisement published on 23rd July, 2024 in Business Standard, English Edition (Mumbai & Kolkata) and Arthik Lipi, Bengali Edition for further details pertaining to the Annual General Meeting. The said advertisement is also available on the website of the Company and of the Stock Exchange where the equity shares of the Company are listed.

For Naga Dhusneri Group Limited

Sd/-
Nidhi Khaitan
Company Secretary & Compliance OfficerPlace: Kolkata
Date : 30th July, 2024**MARKSANS PHARMA LIMITED**

CIN: L24110MH1992PLC066364

Regd. Office: 11th Floor, Grandeur, Veera Desai Extension Road, Oshiwara, Andheri (West), Mumbai - 400053.

Phone: 022 4001 2000; Fax: 022 4001 2011

Website: www.marksanspharma.com;E-mail: companysecretary@marksanspharma.com**NOTICE TO SHAREHOLDERS****Transfer of unclaimed dividend and equity shares of the Company to Investor Education and Protection Fund (IEPF)**

Shareholders are hereby informed that pursuant to the provisions of Section 124 & 125 of the Companies Act, 2013 read with Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016, as amended, (**hereinafter referred as "the Rules"**) those who have not en-cashed any dividends declared by the Company on or after FY2016-17, their unclaimed dividend for FY2016-17 and their shares in which dividend remains unclaimed for seven consecutive years on the ensuing due date i.e. **October 31, 2024** would be liable to be transferred to IEPF Authority. In compliance with the Rules, individual notices has been sent to all the concerned shareholders whose shares are liable to be transferred to IEPF as per the Rules for taking appropriate action(s) on or before **October 30, 2024** failing which the shares will be transferred to IEPF in adherence to the procedures prescribed in the Rules. The Company has also uploaded full details of such shareholders on its website at <http://marksanspharma.com/shares-liable-for-transfer-to-iefp.html>

In this connection, concerned shareholders may please note the following:

- In respect of the shares held in physical form which are liable to get transferred to the IEPF, the Company would issue duplicate share certificate(s) in lieu of the original share certificate(s) held in your name and then inform the Depository by way of corporate action to transfer your shares to the IEPF Authority. Upon issue of such duplicate share certificate(s), the original share certificate(s) which is registered in your name would stand automatically cancelled and be deemed non-negotiable.
- In respect of the shares held in demat form which are liable to get transferred to IEPF, the Company would inform the Depository by way of corporate action to transfer your shares to IEPF Authority.

In the event valid action(s) is not received on or before **October 30, 2024**, the Company shall, with a view to comply with the requirements of the Rules, transfer the unclaimed dividend amount and the corresponding shares to IEPF, as per the procedure stipulated in the Rules, without any further notice. Please note that no claim shall lie against the Company in respect of unclaimed dividend amount and shares transferred to IEPF Authority. Shareholders may note that both unclaimed dividend amount and corresponding shares transferred, including all benefits accruing thereon, if any, can be claimed from IEPF Authority, by making an application in Form IEPF-5 online and sending the physical copy of the same duly signed (as per registered specimen signature) along with requisite documents as enumerated in the said Form IEPF-5 to the Company at its Registered Office or to M/s Bigshare Services Private Limited, RTA of the Company.

For any queries on the above matter, shareholders are requested to contact the Company's Registrar and Share Transfer Agent, Bigshare Services Private Limited at Office No S62, 6th floor, Pinnacle Business Park, Next to Ahura Centre, Mahakali Caves Road, Andheri (East), Mumbai - 400093, Tel. 022 - 62638200, E-mail id: investor@bigshareonline.com

For Marksans Pharma Limited

Sd/-
Harshavardhan Panigrahi
Company SecretaryPlace : Mumbai
Dated : July 31, 2024**IIFL HOME LOAN****IIFL Home Finance Limited**

CIN: U65993MH2006PLC166475

Regd. Office -IIFL House, Sun Infotech Park, Road No. 16V, Plot No. B-23, MIDC,

Thane Industrial Area, Wagle Estate, Thane-400604.

Tel: (91-22) 3929 4000 | Fax: (91-22) 2580 6654 | Website: www.iiflhomefinance.comEmail: secretarialhfc@iiflhomefinance.com

STATEMENT OF STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2024

Amount in crores except otherwise stated

Sl. No.	Particulars	Quarter Ended	Quarter Ended	Year Ended
		June 30, 2024	June 30, 2023	March 31, 2024
		Unaudited	Unaudited	Audited
1	Total Income from Operations	898.10	776.79	3,293.59
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items#)	320.54	296.10	1,328.21
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items#)	320.54	296.10	1,328.21
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items#)	247.31	227.61	1,026.84
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	242.99	223.11	1,019.34
6	Paid up Equity Share Capital	26.34	26.34	26.34
7	Reserves (excluding Revaluation Reserve)	6,682.16	5,749.98	6,421.06
8	Securities Premium Account (included in Sl. No.7-Reserves)	2,969.65	2,969.65	2,969.65
9	Net worth	6,708.51	5,776.33	6,447.41
10	Paid up Debt Capital / Outstanding Debt	17,231.32	14,386.60	17,683.60
11	Outstanding Redeemable Preference Shares	NA	NA	NA
12	Debt Equity Ratio (in-times)	2.57	2.49	2.74
13	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations) (not annualised)			
	1. Basic: (in Rs)	93.88	86.40	389.77
	2. Diluted: (in Rs)	92.77	86.40	388.53
14	Capital Redemption Reserve	NA	NA	NA
15	Debt Redemption Reserve	NA	NA	NA
16	Debt Service Coverage Ratio [(PBT + Interest Expended+ Principal collected from customers during the year)/ (Interest Expended + Principal repayment of the borrowings during the year)]	NA	NA	NA
17	Interest Service Coverage Ratio [(PBT + Interest Expended)/(Interest Expended)]	NA	NA	NA

- Exceptional and/ or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind AS Rules/ AS Rules, whichever is applicable.

Note:

- The above is an extract of the detailed format of quarterly financial results for the quarter ended June 30, 2024 filed with the Stock Exchange under Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly financial results are available on website of National Stock Exchange of India Limited (NSE): www.nseindia.com, BSE Limited (BSE): www.bseindia.com and can be accessed on the Company's website (URL: <https://www.iiflhomefinance.com/financials>)
- For the other line items referred in regulation 52(4) of the listing Regulations, pertinent disclosures have been made to National Stock Exchange of India Limited (NSE): www.nseindia.com, BSE Limited (BSE): www.bseindia.com and can be accessed on website of National Stock Exchange of India Limited (NSE): www.nseindia.com, BSE Limited (BSE): www.bseindia.com.
- The Accounting policies adopted in the preparation of the financial results are consistent with those followed in the previous period/year unless otherwise stated.
- Previous year's/periods figures have been regrouped/reclassified wherever necessary to conform to the current period's presentation.

By order of the Board
For IIFL Home Finance LimitedMonu Ratra
Executive Director & CEO
DIN: 07406284Date: July 29, 2024
Place: Mumbai**ANNOUNCEMENT UNDER REGULATION 23(2) OF SECURITIES AND EXCHANGE BOARD OF INDIA (SUBSTANTIAL ACQUISITION OF SHARES AND TAKEOVERS) REGULATIONS, 2011 AND SUBSEQUENT AMENDMENTS THERETO FOR THE ATTENTION OF THE PUBLIC SHAREHOLDERS OF****HI-KLASS TRADING AND INVESTMENT LIMITED**

(CIN: L51900MH1992PLC066262)

Regd. Office: Office No. 15, 2nd Floor, Plot No. 24, Rehman Building, Veer Nariman Road, Hutatma Chowk, Fort, Mumbai-400001
Tel. No.: +91 22 2287 4084/85 | Email ID: info@hiklass.co.in | Website: www.hiklass.co.in

This announcement is for the withdrawal of the Open Offer ("Withdrawal Announcement") being issued by Mark Corporate Advisors Private Limited, the Manager to the Offer ("Manager"), for and on behalf of Mrs. Mythily Thanghavel ("Acquirer 1"), Mr. Pandamangalam Ramasamy Srinivasan ("Acquirer 2") and Mr. Sadaiaappan Gopalsamy ("Acquirer 3") (hereinafter collectively referred to as "Acquirers") in respect of Open Offer to the Public Shareholders of Hi-Klass Trading and Investment Limited ("Hi-Klass" / "Target Company") pursuant to and in compliance with Regulation 23(2)(a) of the ("SEBI (SAST) Regulations, 2011" / "Regulations"). There are no persons acting in concert ("PACs") with the Acquirers for this Open Offer. This Withdrawal Announcement is to be read with respect to:

- The Public Announcement ("PA") dated February 08, 2023, was filed with SEBI, BSE Limited, Mumbai ("BSE") and the Target Company ("TC") on February 08, 2023 through e-mail and the hard copy of the same was submitted to SEBI on February 09, 2023.
- The Detailed Public Statement ("DPS") published on February 15, 2023 in Business Standard (English-All Editions), Business Standard (Hindi-All Editions) and Navshakti (Marathi-Mumbai Edition). A copy of the same was filed through the Manager to the Offer with SEBI, BSE and the Target Company through e-mail on February 15, 2023. The hard copy of the same was submitted to SEBI on February 15, 2023; and
- The Draft Letter of Offer ("DLof") dated February 22, 2023 was filed with SEBI, BSE and the Target Company on the same date.

All capitalized terms not defined in this Withdrawal Announcement, unless otherwise indicated, shall have the same meaning ascribed to them in the PA, DPS and the DLof.

Withdrawal of the Open Offer:

- The Acquirers have entered into a Share Purchase Agreement ("SPA") with the existing Promoter and Promoter Group ("Promoter Sellers"/"Selling Shareholders") of the Target Company for 17,77,000 Equity Shares representing 28.60% of the Voting Share Capital of the Target Company at a price of ₹5 per equity share. The details of the acquisitions through SPA are as under:

Sr. No.	Name, PAN & Address	Part of Promoter Group (Yes/No)	Details of Shares/Voting Rights held by the Selling Shareholders			
			Pre-Transaction		Post Transaction	
			No of Shares	% vis a vis total Share Capital	No of Shares	% vis a vis total Share Capital
1)	Mr. Sanjay Kumar Jain ("Promoter Seller 1") PAN: AEFPJ2439F Address: 44, Hazra Road, 8 th Floor, Above Mukesh Hyundai Showroom, Ballygunge, Kolkata-700019.	Yes	11,74,200	18.90%	Nil	N.A.
2)	Mrs. Suman Jain ("Promoter Seller 2") PAN: ACQPJ1880K Address: 44, Hazra Road, 8 th Floor, Above Mukesh Hyundai Showroom, Ballygunge, Kolkata-700 019.	Yes	6,02,800	9.70%	Nil	N.A.
Total			17,77,000	28.60%	Nil	N.A.

- The Target Company is registered as a Non-Banking Finance Company with the Reserve Bank of India ("RBI") vide Certificate of Registration bearing no. 13.00134 dated February 26, 1998.
- As the transactions contemplated under the SPA and the acquisition of shares under the Open offer would have resulted in the change in the shareholding of the Target Company in excess of 26.00% of the paid-up equity share capital of the Target Company as well as the Acquirers intended to take over the management of the Target Company by inducting Directors in the Target Company, the approval of the Reserve Bank of India, Mumbai was required to be obtained by the Acquirer/Target Company for the completion of the transaction.
- RBI, Mumbai vide its letter dated July 26, 2024, has stated that change in management and control of the Target Company cannot be acceded to due to lack of regulatory comfort in the compliance culture of the Company. After considering all possibilities, the Acquires and Sellers have decided not to proceed and withdraw the Open Offer. As the RBI approval has not been granted, which is the statutory approval required for proceeding with this Open Offer, the Acquires and Sellers have mutually decided to rescind the said SPA. As a consequence, in terms of Regulations 23(1)(a) of the SEBI (SAST) Regulations, the Open Offer stands withdrawn.
- The necessary intimations to SEBI, BSE and Target Company, as contemplated under Regulation 23(2)(b) of the SAST Regulations is being made simultaneously with this Withdrawal Announcement.

Issued by the Manager to the Offer:

	MARK CORPORATE ADVISORS PRIVATE LIMITED CIN: U67190MH2008PTC181996 404/1, The Summit Business Bay, Sant Janabai Road (Service Lane), Off W. E. Highway, Vile Parle (East), Mumbai-400 057. Contact Person: Mr. Manish Gaur Tel. No.: +91 22 2612 3207/08 E-Mail ID: openoffer@markcorporateadvisors.com Investor Grievance E-Mail ID: investorgrievance@markcorporateadvisors.com SEBI Regn No.: INM000012128
--	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

For and on behalf of the Acquirer and the PACs:

Sd/-	Sd/-	Sd/-
Mythily Thanghavel ("Acquirer 1")	Pandamangalam Ramasamy Srinivasan ("Acquirer 2")	Sadaiaappan Gopalsamy ("Acquirer 3")

Place : Namakkal
Date : July 30, 2024**ajanta pharma limited**

Regd. Office: 'Ajanta House', Charkop, Kandivli (W), Mumbai-67,

Phone - +91-22-66061000, Fax - +91-22-66061200

CIN - L24230MH1979PLC022059

Email - info@ajantapharma.com, Website - www.ajantapharma.com**Extract of Unaudited Consolidated Financial Results for the quarter ended 30 June 2024**

₹ in Crore

	Particulars	Quarter ended 30-Jun-24	Quarter ended 30-Jun-23	Year ended 31-Mar-24
1	Total Income from Operations	1,144.92	1,021.04	4,208.71
2	Net Profit for the period before tax (before exceptional and/or extraordinary items)	322.12	269.04	1,113.93
3	Net Profit for the period before tax (after exceptional and/or extraordinary items)	322.12	269.04	1,113.93
4	Net Profit for the period after tax (after exceptional and/or extraordinary items)	245.77	208.12	816.17
5	Total Comprehensive Income for the period (comprising profit for the period after tax and other comprehensive income after tax)	238.43	205.48	816.98
6	Equity Share Capital	25.07	25.27	25.27
7	Reserve (excluding Revaluation Reserve) as shown in audited balance sheet			3,542.09
8	Earnings Per Share (FV of ₹ 2/- each)			
	(a) Basic - in ₹	19.54	16.53	64.82
	(b) Diluted - in ₹	19.53	16.53	64.77

Key information on Standalone Financial Results :

	Particulars	Quarter ended 30-Jun-24	Quarter ended 30-Jun-23	Year ended 31-Mar-24
	Total Income from Operations	1,077.27	1,014.58	3,971.12
	Profit Before Tax	310.56	275.37	1,096.95
	Profit After Tax	236.03	212.04	807.24
	Total Comprehensive Income	233.60	211.42	804.72

Notes:

- The above financial results have been reviewed by Audit Committee and thereafter approved by the Board of Directors at their meeting held on 30 July 2024.
- On 2 May 2024, Company has announced buy back of its 10,28,881 equity shares, being 0.82% of the total paid up equity share capital at ₹ 2,770 per equity share for an aggregate amount of ₹ 285.00 crores. The buy back opened on 05 June 2024, closed on 11 June 2024 and Company extinguished those shares on 27 June 2024.
- The above is an extract of the detailed format of Quarterly Financial Results filed with Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) regulations, 2015. The full format of the standalone and consolidated financial results for the three months ended 30 June 2024 are available on stock exchange websites www.nseindia.com and www.bseindia.com and on Company's website www.ajantapharma.com.

By order of the Board
For Ajanta Pharma Ltd.

Sd/-

Yogesh M. Agrawal

Managing Director

Mumbai, 30 July 2024

